Skip to main content

Table 5 Changes in IGF-1 concentrations and different tests` scores after vortioxetine treatment

From: Serum insulin-like growth factor-1 as a potential marker for MDD diagnosis, its clinical characteristics, and treatment efficacy validation: data from an open-label vortioxetine study

 

At baseline

n = 48

After treatment

n = 48

Mean change

p

Psychopathological symptoms

 MADRS total score

29 (22–33)

6 (3–11)

20.8

< 0.0001

 CGI-S score

4 (4–5)

1 (1–2)

2.3

< 0.0001

Patient-reported cognitive symptoms

 PDQ-5 total score

7 (4–10)

2 (1–3)

4.7

< 0.0001

Performance-based cognition

 RAVLT immediate recall

51 (43–55)

68 (64–72)

−15.9

< 0.0001

 TMT-B (s)

75 (63–96)

47 (36–60)

30.1

< 0.0001

 DSST

54 (42–61)

62 (51–71)

−9.7

< 0.0001

IGF-1 level (ng/ml)

236 (184–316)

170 (132–210)

89.0

< 0.0001

  1. Data are presented as median (upper-lower quartile); p according to Wilcoxon test (paired samples)